ID   IGROV(CDDP)
AC   CVCL_C1M7
SY   IGROVCDDP
DR   cancercelllines; CVCL_C1M7
DR   Wikidata; Q114311715
RX   PubMed=9443634;
RX   PubMed=9488600;
RX   PubMed=22792399;
CC   Population: Caucasian.
CC   Doubling time: 26 hours (PubMed=9488600).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=9443634; DOI=10.1007/s002800050727;
RA   Ma J.-G., Maliepaard M., Kolker H.J., Verweij J., Schellens J.H.M.;
RT   "Abrogated energy-dependent uptake of cisplatin in a
RT   cisplatin-resistant subline of the human ovarian cancer cell line
RT   IGROV-1.";
RL   Cancer Chemother. Pharmacol. 41:186-192(1998).
//
RX   PubMed=9488600; DOI=10.1007/s002800050744;
RA   Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G.,
RA   Schellens J.H.M.;
RT   "Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a
RT   panel of eight solid-tumor cell lines in vitro.";
RL   Cancer Chemother. Pharmacol. 41:307-316(1998).
//
RX   PubMed=22792399; DOI=10.1371/journal.pone.0040717;
RA   Stordal B., Hamon M., McEneaney V., Roche S., Gillet J.-P.,
RA   O'Leary J.J., Gottesman M.M., Clynes M.;
RT   "Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell
RT   line is mediated by P-glycoprotein.";
RL   PLoS ONE 7:E40717-E40717(2012).
//